There are several risks associated with the use of percutaneous AngioJet thrombectomy, none of which are common, but all of which require some knowledge of the issues to prevent complications.
Although the use of primary angioplasty in the acute myocardial infarction (AMI) setting has been shown to achieve TIMI 3 flow in the majority of patients, there are still some instances in which ...
SAN FRANCISCO (MarketWatch) -- Possis Medical Inc. said Monday it has received marketing approval from the Food and Drug Administration for its AngioJet Ultra Thrombectomy System, the next-generation ...
Boston Scientific ($BSX) announced simultaneous approval to market its AngioJet ZelanteDVT thrombectomy catheter for treating deep vein thrombosis in the U.S., Europe ...
Boston Scientific (NYSE: BSX) has received United States (U.S.) Food and Drug Administration (FDA) approval and CE Mark for the AngioJet™ ZelanteDVT™ thrombectomy catheter to treat deep vein ...
Boston Scientific Corporation BSX is in the process of conducting a Medical Device Correction of certain AngioJet Ultra Consoles, which were shipped to customers without the required operator’s manual ...
1) LMCA: distal 40% lesion. 2) LAD: diffusely atherosclerotic, but unobstructed. 3) LCX: ostial 80% lesion, but there was TIMI 3 flow . 4) RCA: a large vessel and completely occluded proximally soon ...
RAWALPINDI: An angiojet machine worth Rs13.5 million has been installed at the Rawalpindi Institute of Cardiology (RIC). The latest technology is used to remove blood clots from the arteries in ...
Boston Scientific Corporation BSX is in the process of conducting a Medical Device Correction of certain AngioJet Ultra Consoles, which were shipped to customers without the required operator’s manual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results